Prader-Willi Syndrome Association

Prader-Willi Syndrome Association

PWSA was founded in 1975 by parents of children with Prader-Willi syndrome, a complex genetic disorder characterized by insatiable hunger, metabolic challenges, and developmental delays. The association operates from Sarasota, Florida, though its origins trace to grassroots advocacy efforts across the Midwest. Paige Rivard, appointed CEO, now oversees the national organization's programmatic and fundraising operations. The organization channels donor contributions into three primary allocations: medical research grants, crisis intervention for affected families, and professional education for clinicians. Its research funding has supported investigations into hyperphagia drug therapies, hormone replacement protocols, and behavioral intervention models at academic medical centers including the University of Florida and Vanderbilt University. Crisis support includes emergency food-safety planning and residential placement guidance—services distinct from conventional grantmaking. Geographic reach spans all 50 states through a chapter network, with concentrated activity in Florida, California, and the Northeast. PWSA does not manage an investment portfolio or report AUM in the allocator sense. Its annual budget—derived from individual donations, corporate sponsorships, and federal health grants—funds operations and pass-through research awards. The organization maintains no venture arm, no donor-advised fund structure, and no co-investment vehicles. A scientific advisory board reviews research proposals, and funded work occasionally yields intellectual property that returns modest royalties to the association. A structural feature distinguishing PWSA from general pediatric nonprofits is its therapeutic development pipeline: by funding early-stage clinical trials that pharmaceutical companies often avoid in ultra-rare diseases, the association acts as a de facto translational research bridge. This posture places it closer to a disease foundation like the Cystic Fibrosis Foundation's venture-philanthropy model—though at a fraction of the scale and without equity positions in drug developers.